COMMUNIQUÉS West-GlobeNewswire

Zynerba Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
31/05/2018
DEVON, Pa., May 31, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE ), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative [...]
Radient Technologies Inc. Provides Corporate Update on Expansion and ACMPR License Approval
31/05/2018
EDMONTON, Alberta, May 31, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture:RTI) is pleased to provide an update on its manufacturing facility expansion, pending ACMPR license [...]
Sonoma Pharmaceuticals Announces Fiscal Year/Fourth Quarter 2018 Financial Results and Conference Call
31/05/2018
PETALUMA, Calif., May 31, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA ), today announced that financial results for its fiscal fourth quarter 2018, ended March 31, 2018, will be released after [...]
GeneSight® Guided Treatment Significantly Improves Outcomes for Patients with Major Depression Treated in the Primary Care Setting
31/05/2018
New Results from the IMPACT Study to be Presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting SALT LAKE CITY, May 31, 2018 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary [...]
Nasdaq Approves Listing of IMV Inc. Common Shares
31/05/2018
HALIFAX, Nova Scotia, May 31, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (TSX: IMV ) (OTCQX:IMMVD), a clinical stage immunotherapy company, today announced that its common shares have been approved [...]
APTOSE Enters into US$20 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC
31/05/2018
SAN DIEGO and TORONTO, May 31, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO ) (TSX: APS ), a clinical-stage company developing highly differentiated therapeutics that target [...]
Innovate Biopharmaceuticals Scheduled to Present at the Jefferies Global Healthcare Conference in New York on Friday, June 8, 2018, at 11:30AM
31/05/2018
RALEIGH, N.C., May 31, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT ), a clinical stage biotechnology company focused on developing novel therapeutics for immuno-inflammatory [...]
ObsEva SA to Participate in Jefferies Global Healthcare Conference June 5-8, 2018
31/05/2018
Geneva, Switzerland and Boston, MA -May 31, 2018 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that [...]
Merus to Present at the Jefferies 2018 Healthcare Conference
31/05/2018
UTRECHT, The Netherlands, May 31, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS ), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today announced that [...]
Nabriva Therapeutics to Present Lefamulin Data at ASM Microbe
31/05/2018
Potential of Lefamulin to Treat Patients with CABP Against Backdrop of Increasing Bacterial Resistance Presented on Eight Posters DUBLIN, Ireland, May 31, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV [...]
miRagen Therapeutics to Present at Jefferies 2018 Global Healthcare Conference on Thursday, June 7th
31/05/2018
BOULDER, Colo., May 31, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN ), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today [...]
T2 Biosystems Announces Pricing of Public Offering of Common Stock
31/05/2018
LEXINGTON, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO ) today announced the pricing of an underwritten registered public offering of 6,100,000 shares of common stock at a public offering [...]
Arcturus Announces Management Appointments; Company Founder Joseph E. Payne Reinstated as President and CEO
31/05/2018
Industry veteran Dr. Peter Farrell named as Chairman of the Board, Dr. Pad Chivukula reinstated as CSO and COO SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT ), a leading RNA [...]
Axovant to Present at Two Upcoming Investor Conferences
31/05/2018
BASEL, Switzerland, May 31, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXON ) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the Jefferies 2018 Global [...]
Apellis Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
31/05/2018
CRESTWOOD, Ky. and CAMBRIDGE, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS ), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds [...]
BeyondSpring to Present at Upcoming Conferences
31/05/2018
NEW YORK, May 31, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI ), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that [...]
Dova Pharmaceuticals Announces Availability of DOPTELET® in the United States
31/05/2018
DURHAM, N.C., May 31, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA ) today announced the availability of DOPTELET in the United States for the treatment of thrombocytopenia in adult patients with [...]
Scholar Rock Announces Completion of Dosing of First Cohort in Phase 1 Clinical Trial of SRK-015
31/05/2018
CAMBRIDGE, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ: SRRK ), a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in [...]
Madrigal’s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial
31/05/2018
-- Statistically significantly more patients treated with MGL-3196 compared with placebo treated patients achieved a two point reduction in NAS (NAFLD activity score) on biopsy -- -- Statistically significantly more [...]

Pages